NCT01859312View on ClinicalTrials.gov

Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 6, 2013

Primary Completion Date

December 2, 2016

Study Completion Date

December 2, 2016

Conditions
Adrenal InsufficiencyExcess AndrogenCongenital Adrenal Hyperplasia (CAH)
Interventions
DRUG

Hydrocortisone (Solucortef)

Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA). Total daily hydrocortisone dose was calculated based on the patient's estimated cortisol clearance. Rates were established to achieve peak and trough concentrations within the normal circadian cortisol range.

DEVICE

Insulin pump (Medtronic)

Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA)

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

National Institutes of Health Clinical Center (CC)

NIH

NCT01859312 - Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia | Biotech Hunter | Biotech Hunter